Patient clinical characteristics
| Clinical parameters . | n = 52 . | Percentage . |
|---|---|---|
| Median age, years (range) | 58 (22-72) | |
| <50 | 17 | 33 |
| >50 | 33 | 67 |
| Gender | ||
| Female | 23 | 44 |
| Male | 29 | 56 |
| Diagnosis | ||
| AML | 45 | 87 |
| ALL | 7 | 13 |
| Donor | ||
| MUD | 39 | 75 |
| MRD | 13 | 25 |
| Pretransplant conditioning | ||
| Full-intensity Cy, 12 Gy TBI | 11 | 21 |
| Reduced-intensity Fludara, Bu | 31 | 60 |
| Flamsa, 4 Gy TBI | 1 | 2 |
| Flamsa-RIC 2 Gy TBI | 1 | 2 |
| Flamsa-RIC 4 Gy TBI | 3 | 6 |
| Fludara, 2 Gy TBI | 3 | 6 |
| Fludara, 4 Gy TBI | 1 | 2 |
| Fludara, 8 Gy TBI | 1 | 2 |
| aGVHD | ||
| Grade 0-I | 35 | 67 |
| Grade II-IV | 17 | 33 |
| EBV/CMV reactivation | ||
| EBV | 5 | 10 |
| CMV | 18 | 35 |
| Rituximab post-allo-HSCT | 5 | 10 |
| Relapse | 7 | 13 |
| Deceased | 19 | 37 |
| Clinical parameters . | n = 52 . | Percentage . |
|---|---|---|
| Median age, years (range) | 58 (22-72) | |
| <50 | 17 | 33 |
| >50 | 33 | 67 |
| Gender | ||
| Female | 23 | 44 |
| Male | 29 | 56 |
| Diagnosis | ||
| AML | 45 | 87 |
| ALL | 7 | 13 |
| Donor | ||
| MUD | 39 | 75 |
| MRD | 13 | 25 |
| Pretransplant conditioning | ||
| Full-intensity Cy, 12 Gy TBI | 11 | 21 |
| Reduced-intensity Fludara, Bu | 31 | 60 |
| Flamsa, 4 Gy TBI | 1 | 2 |
| Flamsa-RIC 2 Gy TBI | 1 | 2 |
| Flamsa-RIC 4 Gy TBI | 3 | 6 |
| Fludara, 2 Gy TBI | 3 | 6 |
| Fludara, 4 Gy TBI | 1 | 2 |
| Fludara, 8 Gy TBI | 1 | 2 |
| aGVHD | ||
| Grade 0-I | 35 | 67 |
| Grade II-IV | 17 | 33 |
| EBV/CMV reactivation | ||
| EBV | 5 | 10 |
| CMV | 18 | 35 |
| Rituximab post-allo-HSCT | 5 | 10 |
| Relapse | 7 | 13 |
| Deceased | 19 | 37 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Bu, busulfane; CMV, cytomegalovirus; Cy, cyclophosphamide; EBV, Epstein-Barr virus; Flamsa, fludarabine, cytosine-arabinoside and amsacrine; Flamsa-RIC, Flamsa and Endoxan (= cyclophosphamide); Fludara, fludarabine; MRD, matched related donor; MUD, matched unrelated donor; TBI, total body irradiation.